510(k) Submission Services > SaMD & Cybersecurity Utility

FDA 510(k) SaMD Cybersecurity Utility Page

This page is built for device teams preparing software-enabled 510(k) submissions. Use the two tools below to quantify where your cybersecurity package is strong, where it is fragile, and whether your current team capacity can close those gaps before filing.

It is common for teams to discover cybersecurity weaknesses late, after they already consider the submission "complete." That timing creates costly rewrites and inconsistent narratives across device description, risk analysis, software documentation, and labeling. The goal here is to surface practical problems earlier and translate them into concrete owner actions.

Need Full 510(k) Build Support?

Use this utility for planning, then move into a complete submission workflow with structured drafting, review control, and package assembly support.

Go to 510(k) Submission Services

Tool 1: Cybersecurity Evidence Readiness Scorer

Score your submission readiness across architecture exposure, threat-model maturity, SBOM quality, verification depth, and postmarket vulnerability handling. The model highlights your highest-risk blockers first so remediation can be prioritized by impact, not by who argues loudest in review meetings.

Higher exposure reduces baseline readiness score.
More dependencies increase SBOM and vulnerability-tracking burden.
More quality review cycles can raise readiness if time is protected.
Readiness Score
--
Risk Band
--
Top Priority Gaps
--
Estimated Remediation Weeks
--
Run the scorecard to view risk status.

    Tool 2: Vulnerability Response Capacity Estimator

    Use this estimator to compare expected vulnerability-response workload against the real hours your team can sustain without damaging core submission tasks. A queue that grows each month is usually a strong signal that your postmarket plan and premarket narrative will diverge under reviewer scrutiny.

    Expected Monthly Workload
    --
    Available Capacity
    --
    Monthly Surplus / Deficit
    --
    90-Day Backlog Projection
    --
    Run the estimator to view queue stability risk.

    Cybersecurity Evidence Matrix For 510(k) Teams

    Use this matrix as a working checklist during cross-functional reviews. The objective is simple: every major cybersecurity claim should map to evidence, ownership, and an update cadence. Weakness usually appears when one of those three elements is missing.

    Evidence Area Why Reviewers Care Minimum Useful Content Owner Role Review Cadence
    System Architecture and Trust Boundaries Shows where sensitive data and control paths can be compromised. Data-flow map, trust boundaries, interface inventory, external dependencies. Software/Systems Engineering At each architecture change and before submission freeze.
    Threat Model and Abuse Cases Demonstrates that realistic threat paths were identified and prioritized. Threat scenarios, severity rationale, mitigation mapping, residual risk notes. Security + Risk Management Monthly or after major feature changes.
    SBOM and Component Governance Supports vulnerability monitoring across third-party software. Component list, versions, source, maintainer, update strategy, end-of-life flags. Software + DevOps Per build release and supplier update.
    Verification and Validation Evidence Confirms implemented controls actually work as described. Test protocol summary, results, anomaly status, pass/fail rationale, traceability links. QA + Test Engineering Each test cycle and final validation package review.
    Postmarket Vulnerability Management Plan Shows operational ability to monitor, triage, and communicate issues after launch. Detection channels, triage workflow, severity SLAs, customer communication triggers. Quality + Security Operations Quarterly and after incident simulation drills.
    Labeling and User-Facing Security Information Ensures claims made in submission are reflected in user instructions and controls. Security configuration instructions, update guidance, operational limitations. Regulatory + Product At every labeling revision.

    30-60-90 Day Cybersecurity Submission Plan

    Days 1-30: Baseline and Gap Discovery

    • check_circle
      Freeze architecture and dependency inventory inputs for scoring.
    • check_circle
      Run readiness scorer and publish top 5 gaps with owners.
    • check_circle
      Define evidence acceptance criteria for each matrix row.

    Days 31-60: Evidence Hardening

    • check_circle
      Close highest-risk threat-model and SBOM gaps first.
    • check_circle
      Re-run capacity estimator weekly to catch queue drift early.
    • check_circle
      Align software, risk, and labeling narratives to eliminate contradictions.

    Days 61-90: Submission Stabilization

    • check_circle
      Execute final consistency pass across eSTAR sections and attachments.
    • check_circle
      Simulate one response cycle for a high-severity vulnerability scenario.
    • check_circle
      Lock final evidence index with version control and ownership.

    Common Failure Patterns To Watch

    Strong narrative, weak evidence links

    Teams often write a credible cybersecurity story but cannot quickly map each claim to objective evidence. This is the root cause of many slow review loops.

    SBOM exists but is not operational

    An SBOM that cannot be maintained or matched to patch ownership creates a false sense of readiness and weakens postmarket credibility.

    Postmarket plan lacks realistic capacity

    If monthly vulnerability workload exceeds team capacity, your documented process is likely not executable under real operating conditions.

    Inconsistent wording across sections

    Security boundaries and mitigation claims must match across software description, risk analysis, and labeling to avoid avoidable clarifications.

    Related 510(k) Utility Pages

    Core Submission

    Technical Planning

    Sources and References

    Planning-use disclaimer: this page is an operational readiness utility and does not provide legal advice. Teams should confirm final submission strategy against current FDA guidance and product-specific risk context.